In women with distal radial fractures, teriparatide 40 microg did not significantly shorten cortical bridging time versus placebo.
In plain wordsIn women with wrist fractures, the higher teriparatide dose did not significantly shorten healing time versus placebo.
- Peptide
- Teriparatide (PTH 1-34)
- Outcome
- No significant changeTime to cortical bridging, higher dose
- Study
n = 68
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Bone and joint · Musculoskeletal
- Studied dose
- 40 microg daily · injection · 8 weeksAs given in this study (human).
Measurements
- Median bridging time
- 8.8 weeks
- teriparatide 40 microg
- Median bridging time
- 9.1 weeks
- placebo
Source sentences
There was no significant difference between the teriparatide 40 microg versus placebo groups (p = .523).
3 context sentences(design, population, supporting numbers)
The estimated median time from fracture to first radiographic evidence of complete cortical bridging in three of four cortices was 9.1, 7.4, and 8.8 weeks for placebo and teriparatide 20 microg and 40 microg, respectively (overall p = .015).
Postmenopausal women (45 to 85 years of age) who had sustained a dorsally angulated distal radial fracture in need of closed reduction but no surgery were randomly assigned to 8 weeks of once-daily injections of placebo (n = 34) or teriparatide 20 microg (n = 34) or teriparatide 40 microg (n = 34) w…
The primary hypothesis that teriparatide 40 microg would shorten the time to cortical bridging was not supported.